Conduction slowing of the electric impulse that drives the heartbeat may evoke lethal cardiac arrhythmias. Mutations in SCN5A, which encodes the pore-forming cardiac sodium channel ␣ subunit, are associated with familial arrhythmia syndromes based on conduction slowing. However, disease severity among mutation carriers is highly variable. We hypothesized that genetic modifiers underlie the variability in conduction slowing and disease severity. With the aim of identifying such modifiers, we studied the Scn5a 1798insD/ϩ mutation in 2 distinct mouse strains, FVB/N and 129P2. In 129P2 mice, the mutation resulted in more severe conduction slowing particularly in the right ventricle (RV) compared to FVB/N. Pan-genomic mRNA expression profiling in the 2 mouse strains uncovered a drastic reduction in mRNA encoding the sodium channel auxiliary subunit ␤4 (Scn4b) in 129P2 mice compared to FVB/N. This corresponded to low to undetectable ␤4 protein levels in 129P2 ventricular tissue, whereas abundant ␤4 protein was detected in FVB/N. Sodium current measurements in isolated myocytes from the 2 mouse strains indicated that sodium channel activation in myocytes from 129P2 mice occurred at more positive potentials compared to FVB/N. Using computer simulations, this difference in activation kinetics was predicted to explain the observed differences in conduction disease severity between the 2 strains. In conclusion, genetically determined differences in sodium current characteristics on the myocyte level modulate disease severity in cardiac sodium channelopathies. In particular, the sodium channel subunit ␤4 (SCN4B) may constitute a potential genetic modifier of conduction and cardiac sodium channel disease.
C onduction slowing of the electric impulse that drives the heartbeat may evoke cardiac arrhythmias that result in sudden cardiac death. 1, 2 Monogenic inherited diseases associated with conduction slowing, eg, Brugada syndrome, are linked to loss-of-function mutations in SCN5A, the gene that encodes the pore-forming ␣ subunit of the cardiac sodium channel (Nav1.5). 3, 4 Such primary arrhythmia syndromes ("channelopathies") are highly relevant models to resolve arrhythmia mechanisms in common diseases, because the role of electrophysiological changes can be studied in isolation as confounders, eg, gross structural derangements, are absent. Moreover, because reduced penetrance and variable expressivity occur in these, as in many other, monogenic diseases, these models allow for dissection of the role of genetic modifiers which are likely to be of clinical relevance. For instance, in Brugada syndrome patients, disease penetrance may be as low as 12.5%. 5 Furthermore, we have previously reported variable severity of conduction disease in a large Dutch kindred carrying the SCN5A-1795insD founder mutation associated with conduction disease and Brugada syndrome. 6, 7 Although gender and environmental factors are likely determinants of intrafamilial heterogeneity in ECG parameters and symptomatology, genetic background has also been proposed to affect the phenotypic consequences of ion channel gene mutations. However, molecular identification of genetic modifiers of disease severity in cardiac ion channelopathies is still rare. 8 In this study, we aimed to identify novel genetic modifiers of conduction slowing. To overcome the com-plexities associated with defining modifiers in human populations, we studied transgenic mice carrying the mouse homolog (Scn5a 1798insD/ϩ ) of the SCN5A-1795insD mutation. Scn5a 1798insD/ϩ mice recapitulate various clinical features of patients with this mutation, including conduction slowing and bradycardia. 9 We studied the effect of the Scn5a 1798insD/ϩ mutation in mice of 2 distinct inbred genetic backgrounds, allowing for unbiased assessment of the role of modifier genes on phenotype severity, without potential confounding influences such as environmental factors. 10 We found that these strains display profoundly different severities of conduction disease, along with differences in cardiac gene expression profiles. In particular, ventricular expression levels of the sodium channel auxiliary subunit ␤4 (encoded by the Scn4b gene) were drastically reduced in the mouse strain with the most severe conduction phenotype, pointing to differences in sodium channel complex composition, and sodium current characteristics between the 2 strains. This was subsequently confirmed by patch-clamp studies on isolated myocytes, demonstrating differences in sodium channel kinetics between the 2 strains, predicted to underlie the observed variation in severity of conduction disease.
Materials and Methods

Generation of Scn5a 1798insD/؉ Mice
Heterozygous Scn5a 1798insD/ϩ mice were generated and genotyped as previously described. 9 Male chimeras were crossed with 129P2/ OlaHsd females to give F1 heterozygous offspring (129P2-Scn5a 1798insD/ϩ ) and maintained in this genetic background by backcrossing with 129P2 mice (Harlan). 129P2-Scn5a 1798insD/ϩ mice were outcrossed with FVB/N mice (Charles River Laboratories) for Ն6 generations, establishing a second line on the FVB/N background (FVB/N-Scn5a 1798insD/ϩ ). Experiments were performed on adult (10-to 18-week-old) mice, in accordance with governmental and institutional guidelines for animal use in research.
Electrocardiographic Measurements and Epicardial Mapping Experiments
Details on ECG recordings, analysis, and flecainide acetate administration (20 mg/kg bodyweight IP) are provided in the online data supplement, available at http://circres.ahajournals.org. Epicardial mapping experiments were performed on isolated, Langendorff-perfused hearts as previously described (see the online data supplement). 9
Microarray Analysis and Quantitative RT-PCR
For microarray analysis, RNA from right ventricle (RV) samples of wild-type (WT) and Scn5a 1798insD/ϩ mice of both strains were compared (nϭ3 in each group) using Applied Biosystems Mouse Genome Survey Microarrays (see the online data supplement). mRNA expression levels of selected genes were validated by quantitative RT-PCR (see the online data supplement).
Western Blot Analysis and Antibodies
Western blot analysis on membrane protein fractions isolated from mouse RV and left ventricle (LV) tissue was carried out as described in the online data supplement.
Patch-Clamp Experiments
LV myocytes were isolated by enzymatic dissociation as previously described. 9 Action potentials (APs) were measured at 36°C in the perforated whole-cell configuration of the patch-clamp technique. Sodium current density, activation, and inactivation parameters were determined at room temperature using conventional voltage clamp protocols (see Figure 5 ). For details on bath and pipette solutions, data acquisition, and analysis, see the online data supplement.
Computer Simulations
Upstroke velocity in single isolated myocytes was simulated using the Luo and Rudy dynamic model of the mammalian subepicardial ventricular myocyte of LV origin ("LRd model"), 11 with the transient outward current I to conductance set to 0.5 mS/F and the I to equations as described previously. 12 Conduction velocity was assessed in linear strands of 100 longitudinally or transversally coupled LRd myocytes. The strain difference in I Na kinetics was incorporated as a ϩ5-mV shift in the I Na steady-state activation curve and the effect of Scn5a 1798insD/ϩ as a 50% reduction in the fully-activated I Na conductance (for details, see the online data supplement).
Statistical Analysis
Data are presented as meansϮSEM. Differences between groups were analyzed by (un)paired Student's t test, nonparametric test, or ANOVA as appropriate. The level of statistical significance was set to PϽ0.05.
Results
Mouse Characteristics
Heterozygous Scn5a 1798insD/ϩ offspring of both FVB/N and 129P2 mouse strains were born at a Mendelian frequency; homozygotes were not viable. No differences in general appearance, (cardiac) morbidity, or lifespan was observed between Scn5a 1798insD/ϩ mice of either strain.
Strain-Dependent Severity of Conduction Slowing on Surface ECG
PQ interval, QRS duration, and QTc interval at baseline were significantly longer in Scn5a 1798insD/ϩ (MUT) mice than in WT mice in both strains ( Figure 1A and 1B). Whereas 129P2-WT mice showed increased baseline PQ-and QRS intervals compared to FVB/N-WT, the mutation had more severe effects on ECG parameters in 129P2 mice than in FVB/N mice, pointing to an interaction between genotype and strain (2-way ANOVA: PQ, PϽ0.0005; QRS, PϽ0.05; QTc, PϽ0.05; Figure 1B ). No differences in RR interval were observed between any of the groups ( Figure 1B ). Administration of the sodium channel blocker flecainide further exacerbated the differences in conduction parameters between WT and MUT mice, and between MUT mice of both strains. Strikingly, an almost 3-fold larger increase in QRS duration (⌬QRS) at 5 minutes after flecainide was observed in 129P2-MUT compared to FVB/N-MUT mice (2-way ANOVA PϽ0.05; Figure 1A and 1C). Furthermore, flecainide induced extreme sinus bradycardia and/or sinus arrest in 11 of 13 (85%) 129P2-MUT but in only 8 of 16 (50%) FVB/N-MUT mice. In addition, ventricular arrhythmias (ventricular extrasystoles and short runs of ventricular tachycardia; Figure 1A ) occurred after flecainide administration in 6 of 13 (46%) 129P2-MUT mice but in none of the 16 FVB/N-MUT mice. No atrial or ventricular arrhythmias were observed in WT mice of either strain. Biochemical analysis showed similar plasma flecainide concentrations in all 4 experimental groups (data not shown). Thus, the presence of the Scn5a 1798insD/ϩ mutation resulted in more severe conduction slowing in 129P2 mice than in FVB/N mice. These effects were independent of differences between WT mice of both strains, indicating an interaction between the Scn5a 1798insD/ϩ mutation and mouse genetic background.
Conduction Slowing in Isolated Hearts
Epicardial mapping experiments in isolated Langendorffperfused hearts of 129P2-MUT mice showed similarities with our previous observations in FVB/N-MUT mice, 9 including conduction slowing and reduced transverse conduction velocity in RV but not LV ( Figure 2 and Table 1 ). However, 129P2-MUT hearts displayed more pronounced RV conduction slowing during both sinus rhythm and basic stimulation as compared to FVB/N-MUT ( Figure 2B ). Furthermore, longitudinal conduction velocity was decreased in RV of 129P2-MUT mice but not in FVB/N-MUT (Table 1) .
Right Ventricular mRNA Expression Differences Between Strains
To investigate the molecular basis of the strain-dependent effects on severity of conduction disease in Scn5a 1798insD/ϩ mice, we performed cardiac mRNA expression profiling in both strains using whole-genome microarrays. Because conduction slowing in Scn5a 1798insD/ϩ mice was more severe in RV than LV, we compared mRNA expression profiles of RV samples in young mice (age 10 to 12 weeks) of both strains and genotypes (MUT and WT). After quality control, 17 543 genes were available for comparative analysis between the groups. Results from 2-way ANOVA indicated significant differences in gene expression for strain effect but not for genotype (see Figure I in the online data supplement). Because genotype showed no effect, WT and MUT samples for each strain were pooled followed by 1-way ANOVA analysis for strain effects. Seventy-six genes (listed in Online Tables I and II) were found to be differentially expressed between both strains (PϽ0.001; Online Figure  II ), of which, 3 encoded ion channel subunits expressed in heart. 129P2 mice displayed a more than 20-fold lower RV expression of Scn4b, which encodes the sodium channel auxiliary subunit ␤4, as compared to FVB/N. Two other ion channel genes were also differentially expressed, namely Kcne1, encoding a potassium channel accessory subunit, and Scn10a encoding the sodium channel poreforming subunit Nav1.8. A subset of the identified 76 genes was subsequently validated by quantitative RT-PCR, which revealed similar results to those obtained from the arrays (see Online Figure III ).
Reduced Ventricular Scn4b mRNA and ␤4 Protein Expression in 129P2 Mice
Because the sodium channel auxiliary subunit ␤4 was found to be differentially expressed between the 2 strains on microarray analysis, we evaluated the expression levels of all known sodium channel ␤ subunits in RV and LV of both strains by quantitative RT-PCR ( Figure 3A) . Scn4b mRNA levels displayed the most striking difference between the 2 strains, both in RV and LV, with expression being 12-to 15-fold lower in 129P2 tissue compared to FVB/N. Although Scn1b mRNA levels were significantly reduced in both RV and LV tissue of 129P2 mice compared to FVB/N mice, the fold change was only Ϸ2-fold in both RV and LV. Scn2b mRNA displayed an Ϸ2-fold increase in LV of FVB/N mice compared to 129P2 but was not significantly different in RV between both strains. In contrast, Scn3b mRNA levels were Ϸ3-fold lower in RV of 129P2 compared to RV of FVB/N, but there were no differences in LV levels of Scn3b between the strains. Thus, only Scn1b and Scn4b mRNA were consistently reduced in both RV and LV of 129P2 compared to FVB/N, and we further investigated the effects that these differences in mRNA levels had on levels of the corresponding protein by Western blot analysis. ␤1 protein levels were not significantly different between the 2 strains in 3 independent Western blot experiments on LV tissue ( Figure 3B ). In contrast, 3 independent Western blot experiments on LV tissue samples consistently showed abundant ␤4 protein expression in FVB/N but low to absent levels in 129P2 ( Figure 3C ). Both Scn5a mRNA and Nav1.5 protein expression levels were not different between RV and LV of 129P2 and FVB/N mice ( Figure 3A and 3D) , indicating a substantial decrease in the auxiliary subunit ␤4 relative to the amount of Nav1.5 ␣ subunit in ventricular tissue of 129P2 mice.
Action Potential Upstroke Velocity in Isolated Myocytes
To evaluate the functional consequences of the observed differences in ventricular ␤4 protein levels between the strains, and its impact on conduction, we first studied action potential (AP) upstroke velocity (dV/dt max ) as a measure of sodium channel availability in ventricular myocytes isolated from WT and Scn5a 1798insD/ϩ mice of both strains. At the physiological stimulation rate of 8 Hz (but not 2 Hz), dV/dt max was smaller in myocytes of 129P2-WT mice than in those of FVB/N-WT mice, and FVB/N-MUT and 129P2-MUT mice displayed similar relative reductions in dV/dt max with respect to their WT littermates at 2 and 8 Hz ( Figure 4A and 4C). Thus, the Scn5a 1798insD/ϩ mutation decreased sodium channel availability to a similar degree in both strains. However, 129P2-MUT mice displayed the lowest absolute values for dV/dt max , in accordance with our finding that 129P2-MUT mice showed more pronounced conduction slowing (increased QRS width) on ECG analysis. Moreover, the mutation significantly prolonged the AP in both strains, with 129P2-MUT mice overall displaying the longest AP duration at 90% repolarization (APD 90 ) at 8 Hz ( Figure 4B and 4D).
Differences in Sodium Current Characteristics Between Strains
To further elucidate the electrophysiological effects of altered sodium channel complex composition, we next compared sodium current characteristics in isolated myocytes between mouse strains. As expected, 9 the Scn5a 1798insD/ϩ mutation in itself did not affect channel kinetics (in either strains) but resulted in a drastic reduction in sodium current density in MUT compared to WT mice of both strains ( Figure 5A and Table 2 ). When comparing the 2 strains, no differences in sodium current density (measured at a holding potential of Ϫ20 mV) or inactivation parameters were observed between 129P2 and FVB/N myocytes ( Figure 5A and Table 2 ). However, activation kinetics from 129P2 myocytes were significantly altered, resulting in a 5-mV positive shift in steady-state activation in 129P2-WT and 129P2-MUT myocytes compared to FVB/N-WT and FVB/N-MUT, respectively ( Figure 5B and Table 2 ).
Computer Simulations
To investigate whether the observed differences in sodium current activation kinetics between FVB/N and 129P2 myocytes explain, at least in part, the differences in severity of conduction disease between the 2 strains, we performed computer simulation experiments using the LRd model. Figure 6A shows dV/dt traces during the AP upstroke of an LRd model cell in response to the stimulation protocol applied in our patch-clamp experiments, ie, with a stimulus current amplitude such that the AP upstroke started just before the end of the 3-ms stimulus. Maximum upstroke velocity determined from these dV/dt traces ( Figure 6B ) amounted to 394, 329, 239, and 194 V/sec in FVB/N-WT, 129P2-WT, FVB/N-MUT, and 129P2-MUT, respectively, thus predicting a similar trend as observed in our patch-clamp experiments ( Figure 5 ). Figure 6C and 6D illustrates the predicted effects of alterations in sodium current on AP propagation and conduction velocity. The ϩ5-mV shift in I Na activation of 129P2-WT compared to FVB/N-WT (obtained from our patch-clamp experiments) results in a decrease in conduction velocity from 50 to 44 cm/sec, whereas the 50% reduction in I Na conductance of FVB/N-MUT compared to FVB/N-WT decreases conduction velocity to 39 cm/sec. The combined effect of the shift in I Na activation and reduction in I Na conductance amounts to a decrease in conduction velocity (measured at a holding potential of Ϫ20 mV), *PϽ0.05 vs FVB/N-MUT; †PϽ0.05 vs FVB/N-WT.
Table 2. Mean Sodium Current Density and Activation and Inactivation Parameters Obtained From Voltage Clamp Experiments in WT and MUT Myocytes of FVB/N and 129P2 Mice
to 32 cm/s for 129P2-MUT. Qualitatively similar results were obtained for transverse conduction velocity (data not shown).
Discussion
To elucidate the role of genetic background on modulation of cardiac conduction disease in sodium channelopathy, we conducted in vivo, in vitro, and cellular electrophysiological studies, along with gene expression analysis, in transgenic mice from 2 distinct inbred strains both carrying the Scn5a 1798insD/ϩ mutation. We demonstrate different severity of conduction disorder in the 2 mouse strains, along with variation in cardiac sodium channel ␤-subunit expression and differences in sodium current characteristics on the myocyte level.
In ventricular myocytes, multiple redundant mechanisms exist that ensure maintenance of normal cardiac conduction, and multiple stressors may be required to reduce conduction reserve sufficiently to elicit electric disturbances and arrhythmias. [13] [14] [15] The consequences of a decreased conduction reserve may remain concealed during normal physiological conditions but render the heart more susceptible to conduction slowing and arrhythmia in the presence of an additional stressor, eg, a sodium channel mutation and/or drug challenge. 129P2 mice possess reduced conduction reserve compared to FVB/N mice, as evidenced by their more severe conduction disease phenotype as a consequence of the Scn5a 1798insD mutation. Their conduction reserve is further compromised after drug challenge with the sodium channel blocker flecainide, which also renders them more susceptible to arrhythmias.
The variability in cardiac conduction disease (including sinoatrial, atrioventricular, and intraventricular conduction abnormalities) between the FVB/N and 129P2 mouse strains is reminiscent of the highly variable disease severity observed in patients carrying the SCN5A-1795insD mutation 6 and points to a significant role for genetic background. Although cardiac conduction (reserve) is most likely a polygenic trait controlled by multiple genetic factors influencing various pathway (such as cell-cell communication, tissue architecture, etc), we propose that the genetically determined low levels of ␤4 observed in 129P2 mice compared to FVB/N contribute to the decreased conduction reserve in this strain. Compared to FVB/N, sodium current measurements in myocytes from 129P2 mice showed a significant positive shift in steady-state activation. Using computer simulations, this shift in activation kinetics was predicted to slow conduction. Thus, although cardiac conduction in general may be affected by numerous factors, our current observations imply intrinsic differences between the 2 mouse strains at the level of the sodium current, which are very likely related to differences in sodium channel composition. In addition, upstroke velocity is slower in 129P2 and thus may additionally contribute to reduced conduction. Also, at mouse physiological heart rates (Ն6 Hz), AP duration tended to be prolonged in 129P2, a consequence of which was that time for sodium channel recovery from inactivation is shortened. This may reduce sodium channel availability even further, emphasizing the complex inheritance of this trait.
Interestingly, a mutation in the gene encoding the intracellular scaffolding A-kinase anchoring protein 10 (AKAP10) also affects 129P2 and FVB/N mice differentially. 129P2 mice carrying a mutation in AKAP10 disrupting the final 51 amino acids display an early mortality phenotype, whereas FVB/N mice with the same mutation are protected. 16 AKAP10 regulates vagus nerve sensitivity and atrioventricular conduction, and the functional AKAP10 polymorphism I646V is associated with shorter PR intervals in humans and is disproportionately low among healthy older people. 17 These findings are in line with our observation of a more severe conduction phenotype in 129P2 mice and provide further support to the idea that the 129P2 and FVB/N strains differ in genetic susceptibility to conduction disturbance.
Mutations in SCN5A have been linked to a number of arrhythmia syndromes, including Brugada syndrome, conduction disease, sinus node dysfunction, and long QT syndrome. 18 Various SCN5A mutations have been associated with mixed phenotypes, a presentation that has become known as "overlap syndrome of cardiac sodium channelopathy." 19 The reduced disease penetrance and variable disease expression observed in these syndromes clearly suggests a potential role for genetic modifiers. 7, 8, 20, 21 The genetic variation that underlies interindividual variability in phenotype in carriers of the same disease-causing mutation, as shown in our study and previous reports, 6, 7, 20, 21 may reside within the disease locus itself or at other loci in the genome. With respect to variation within the SCN5A gene itself, a number of studies have pointed to a role for the common H558R polymorphism. 22, 23 Furthermore, we have previously demonstrated that a haplotype in the promoter region of SCN5A, common in Asians, affects SCN5A gene expression and leads to variability in cardiac conduction at baseline and in response to drug block. 24 We now provide evidence that variability in expression level of an auxiliary subunit (␤4) of the cardiac sodium channel also impacts on cardiac conduction and modulates the effect of mutations in SCN5A. Variation in gene expression is abundant in all organisms studied to date, and it is becoming increasingly clear that modifications in gene regulation could be responsible for much of the observed phenotypic variation in natural populations. 25 DNA variation affecting Scn4b transcript abundance could occur either through cis-acting DNA variation at the Scn4b locus itself or through trans-acting DNA variation located in genes encoding transcription factors or proteins affecting RNA processing. Future genomic studies in these inbred strains will ultimately provide further insight into this issue.
Sodium channel ␤ subunits are auxiliary subunits to the pore-forming ␣ subunit of sodium channels that influence sodium channel density and kinetics 26 -28 and therefore constitute excellent candidates as modifiers of cardiac conduc-tion. We have recently shown that mutations in the SCN1B gene encoding the ␤1 subunit are associated with decreased Nav1.5 sodium current and lead to conduction disease and Brugada syndrome. 29 The ␤4 subunit has only recently been identified 30 and its functional role is not fully resolved. It is, however, known to be highly expressed in brain, heart, and skeletal muscle, similar to ␤1. 31 In brain, downregulation of ␤4 has been associated with sodium channel dysfunction and neurite degeneration in Huntington's disease. 32 In mouse cardiomyocytes, the ␤4 subunit appears to be preferentially localized at the intercalated disc. 33 The importance of the ␤4 subunit for cardiac function is underscored by the recent association of a missense mutation in SCN4B with long QT syndrome. 34 This mutation was shown to enhance persistent sodium current on cotransfection with SCN5A in HEK293 cells. Crucially, in this study, a physical interaction between Nav1.5 and ␤4 was described, further pointing to a regulatory role of ␤4 in cardiac sodium channel function. 34 Although the predominant involvement of the RV in conduction slowing observed in Scn5a 1798insD/ϩ mice of both strains correlates well to the clinical features of Brugada syndrome, its exact mechanism remains unclear. Possible contributing factors include transmural differences in sodium channel distribution, 35 regional differences in inward rectifier current (I K1 ) density, 36, 37 and differences in size and structure between RV and LV. 38 In the severely affected 129P2 strain, RV conduction velocity was slower than in the less severely affected FVB/N strain. Because Scn4b expression was lower in RV of 129P2 versus FVB/N, and in view of our findings at the sodium channel level between these 2 strains, SCN4B may constitute a likely modifier gene of RV conduction, potentially also modulating the Brugada syndrome phenotype.
In conclusion, we identified the sodium channel auxiliary subunit ␤4 as a potential genetic determinant of conduction and a disease modifier in sodium channelopathy. The identification of genetic determinants of disease expressivity may facilitate diagnosis, risk stratification, and treatment selection in patients with cardiac sodium channel disease. Our findings may spawn future studies that are aimed at investigating the relevance of ␤4 in common diseases associated with decreased cardiac excitability, including heart failure and myocardial ischemia.
